Home Patent Forecast® Sectors Log In   Contact  
Enjoy your FREE PREVIEW which shows only 2024 data and 25 documents. For full access, try it free at any time.        


GW Pharmaceuticals, Plc

GW Pharmaceuticals (GW) is a British biopharmaceuticals company now owned by Jazz Pharmaceuticals. GW is focused on developing and marketing therapeutics based on plant-derived cannabinoid compounds. GW saw early success with Epidolex, the first cannabis plant-derived medicine approved by the FDA, which is used to treat patients with rare epilepsy diseases (Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex). GW has also developed Sativex, which is used to treat patients with multiple sclerosis. GW is primarily focused on neurological conditions, including conditions with both orphan and non-orphan status.

News and Insights

GW Pharmaceuticals, Plc Owned Patent Documents in this Patent Forecast
Loading Documents...